US$ 24.18
obesity drug news today glp-1 october 2025 therapies are changing care. What does WHO recommend? Here's what you need to know KFF Health News | Lots
Description
C.et al (2017)
Future research on GLP-1-based medicines for weight reduction must prioritize the precise evaluation of muscle mass, composition, and functionality to clarify their impact on muscular health

ShapiroWilk test was used to check the normality of the variable distribution

In the planned exploratory analysis ICP was measured continuously for the first 2.5 h after dosing and then between 24.00 and 07.00 h overnight following the first dose

doi: 10.2337/dc19-S009 21 EngCKramerCKZinmanBRetnakaranR
